ORIGINAL RESEARCH article

Front. Neurol.

Sec. Stroke

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1520309

This article is part of the Research TopicAdvances in Diabetes and Hypertension ResearchView all 15 articles

Role of Human Urinary Kallikrein in Reducing Progressive Ischemic Stroke among Acute Ischemic Stroke Patients with Concurrent Hypertension and Diabetes: A Hospital-based Retrospective Cohort Study

Provisionally accepted
Zeyang  ZhengZeyang ZhengYuelong  LiYuelong LiShanshan  YangShanshan YangYuanqi  XuYuanqi XuLian  YiLian YiYushuang  LiuYushuang LiuLi  ZhangLi ZhangZhongling  ZhangZhongling Zhang*
  • Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

The final, formatted version of the article will be published soon.

Background Progressive ischemic stroke (PIS) poses significant challenges in the management of acute ischemic stroke (AIS), with higher morbidity and mortality rates, especially among patients with vascular risk factors such as hypertension and diabetes. This study evaluates the efficacy of human urinary kallidinogenase (HUK) in reducing the incidence of PIS in patients with AIS, with a particular focus on subgroups based on vascular pathology and thrombolytic treatment.Methods This retrospective cohort study included 916 patients with AIS treated at a single tertiary care center between January 2022 and September 2023. The patients were divided into two groups based on whether they received HUK treatment in addition to standard care or standard care alone. The primary outcome was the incidence of PIS. Independent sample t-tests or chi-squared tests were used for univariate analysis between groups to identify potential predictors associated with the occurrence of PIS, with factors achieving a p-value < 0.1 considered for multivariate binary logistic regression analysis. Multivariate analysis adjusted for potential confounders to determine independent predictors significantly associated with PIS. The significance threshold was set at p < 0.05. In addition, subgroup analyses were conducted based on stroke subtype (TOAST classification), thrombolysis treatment, and infarction location.Results HUK treatment significantly reduced the incidence of PIS (P < 0.001), with the most notable effects observed in patients with large-artery atherosclerosis and small-artery occlusion, those not undergoing intravenous thrombolysis, and those with anterior circulation infarctions. Conversely, no significant reduction was noted in patients with cardioembolic stroke, other etiologies of infarction, intravenous thrombolysis, posterior circulation infarctions, or both anterior and posterior circulation infarctions. Factors such as low body mass index (BMI) and high activated partial thromboplastin time are associated with an increased risk of PIS. Conclusion HUK treatment appears to be an effective strategy for reducing the risk of PIS in patients with AIS, particularly in those at higher risk owing to specific vascular pathologies. These findings support the use of HUK in clinical practice to improve the outcomes of patients with stroke. Future prospective, multicenter, randomized controlled trials are warranted to validate these findings and further elucidate the underlying mechanisms.

Keywords: Acute ischemic stroke, Progressive ischemic stroke, human urinary kallikrein, stroke management, Vascular pathology

Received: 31 Oct 2024; Accepted: 26 May 2025.

Copyright: © 2025 Zheng, Li, Yang, Xu, Yi, Liu, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhongling Zhang, Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.